Back
Science

Study Finds Barrett's Oesophagus is Universal Precursor to Oesophageal Adenocarcinoma

Generated on: Last updated: 1 sources
View source

Landmark Study Confirms Barrett's Oesophagus as Universal Precursor to Common Oesophageal Cancer

A comprehensive study published in Nature Medicine has concluded that Barrett's oesophagus is the universal precursor to oesophageal adenocarcinoma (OAC), the most common form of oesophageal cancer. The research, analyzing data from 3,100 OAC patients, found no genomic evidence for alternative pathways to the disease.

The findings suggest that in many advanced cancer cases, the original Barrett's tissue may be destroyed by the tumor, making it undetectable by standard endoscopy.

Study Methodology and Scope

Researchers from the University of Cambridge's Li Ka Shing Early Cancer Institute conducted an analysis of epidemiological, clinical, and genomic data.

  • Patient Cohort: The study included data from 3,100 OAC patients who underwent surgery. Participants were recruited from 25 medical centers across the United Kingdom.
  • Genomic Analysis: Scientists performed whole genome sequencing on tumors from 710 patients. Additionally, whole exome sequencing was conducted on multiple tumor samples from 87 patients to examine genomic patterns in detail.
  • Research Aim: The primary objective was to determine if OAC can develop without Barrett's oesophagus as a precursor, given that approximately half of OAC patients show no detectable Barrett's tissue at diagnosis.

Key Findings

The analysis yielded several consistent results:

  • Prevalence of Prior Diagnosis: Among the study participants, 35% had a recorded prior diagnosis of Barrett's oesophagus.
  • Indistinguishable Genomic Profiles: The DNA, mutations, genomic patterns, and cellular identity within OAC tumors were found to be essentially indistinguishable. This was true regardless of whether Barrett's oesophagus was visible during endoscopy at the time of cancer diagnosis.
  • Correlation with Tumor Stage: The primary difference between the groups was the stage of the cancer. Patients without visible Barrett's oesophagus at diagnosis tended to have more advanced tumors.
  • Presence of Molecular Biomarkers: Biomarkers specifically associated with Barrett's oesophagus, namely the proteins TFF3 and REG4, were present in oesophageal cells at all stages of the disease, including in tissue samples taken before cancer development.

The researchers stated they found no evidence for an alternative pathway to oesophageal adenocarcinoma other than through Barrett's oesophagus.

Background and Context

  • Oesophageal Cancer Burden: Oesophageal cancer is the sixth most deadly cancer worldwide. Oesophageal adenocarcinoma (OAC) is its most common form in Western countries, and its incidence is increasing. It is often diagnosed at an advanced stage when treatment options are more limited.
  • Barrett's Oesophagus: This condition, where the lining of the oesophagus changes to resemble the lining of the intestine, is visible as a distinct patch during endoscopy. It affects an estimated 1 in 100 to 200 people in the UK.
  • Established Risk: It is estimated that between 3% and 13% of individuals with Barrett's oesophagus will develop OAC in their lifetime.
  • Prior Diagnostic Challenge: Before this study, the fact that roughly 50% of OAC patients had no detectable Barrett's oesophagus at diagnosis had raised questions about its role as a necessary precursor.

Researcher Statements

Professor Rebecca Fitzgerald (University of Cambridge):

"Cancer generally takes many years to evolve, giving us a window of opportunity to catch it before it develops into a life-threatening condition. Screening and preventative strategies can have a massive impact on the number of people who die from cancer, but if the link between precancers and cancer is unproven or unclear, screening programmes risk doing more harm than good."

Dr. Shahriar Zamani (Joint First Author):

"We found no evidence for an alternative pathway to oesophageal adenocarcinoma other than Barrett's oesophagus. Because it seems to be the universal precursor, detecting Barrett's oesophagus earlier could offer a clearer route to preventing oesophageal cancer."

Dr. Lianlian Wu (Joint First Author):

"What we need now are more sensitive, minimally invasive tests that identify people at risk based on molecular markers rather than relying solely on visible changes found during endoscopy."

Dr. Dani Skirrow (Cancer Research UK):

"Detecting the earliest signs that cancer might develop gives us the opportunity to intervene and potentially prevent the disease. This research helps to clarify how the most common type of oesophageal cancer begins and, crucially, shows that the earliest signs are detectable even when doctors can't see them. This opens the door to future tests that look for molecular clues of hidden pre-cancerous changes."

Research Support and Related Developments

  • Funding: The research was supported by Cancer Research UK, the Medical Research Council, and the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre.
  • Diagnostic Innovation: Professor Fitzgerald has led the development of a capsule sponge test, a minimally invasive method for diagnosing Barrett's oesophagus that can be administered in a primary care (GP surgery) setting.